How Long Is the NMPA Review Period for Cell and Gene Therapy Products in China?

For foreign biotech companies seeking to bring cell and gene therapy (CGT) products to the Chinese market, understanding the National Medical Products Administration (NMPA) review timeline is essential for strategic planning, budgeting, and investor communication. Unlike conventional small-molecule drugs or even standard biologics, cell and gene therapies face a distinct regulatory pathway in China, shaped by the Center for Drug Evaluation (CDE) under the NMPA, with review periods that differ significantly from both Western jurisdictions and China’s own chemical drug review timelines.

This FAQ provides a comprehensive breakdown of the NMPA review period for cell and gene therapy products, covering the initial IND review, clinical trial phases, market authorization (NDA/BLA) review, and the various expedited pathways that can significantly compress these timelines. The information reflects the regulatory framework as of 2025–2026, including recent reforms under China’s Drug Administration Law and the 2024 amendments to the Provisions for Drug Registration.

Standard NMPA Review Timelines for CGT Products

The NMPA review timeline for cell and gene therapy products follows the general framework established for all innovative biologics but incorporates specific considerations due to the novel nature of these products. The review process is divided into two major phases: Investigational New Drug (IND) review and New Drug Application (NDA) review.

IND Review Timeline

The IND review is the first regulatory hurdle for any CGT product seeking to conduct clinical trials in China. The standard process unfolds as follows:

• Formal Review (Pre-acceptance): 5 working days. The CDE checks for completeness of the submission package. Incomplete applications receive a notice requiring rectification within a specified period.
• Technical Review (Primary Phase): 60 working days (approximately 3 calendar months) from the date of acceptance. This is the standard timeline for innovative drugs, including CGT products, under the 2020 Provisions for Drug Registration.
• Supplementary Review (if required): 40 working days. If the CDE requests additional data or clarifications, the clock pauses until the sponsor responds, and the review resumes with this supplementary period.
• Overall IND Timeline: Typically 60–100 working days (3–5 calendar months) from submission to IND approval, assuming no major deficiencies are identified.

NDA/BLA Review Timeline

The market authorization review for cell and gene therapy products is substantially longer than the IND review, reflecting the comprehensive evaluation of safety, efficacy, and manufacturing quality required before commercial approval:

• Standard NDA Review: 200 working days (approximately 10 calendar months). This is the statutory timeline for innovative drug applications under Article 96 of the Provisions for Drug Registration.
• Priority Review NDA: 130 working days (approximately 6–7 calendar months). CGT products that demonstrate significant clinical advantage over existing therapies or address an unmet medical need may qualify for this accelerated pathway.
• Breakthrough Therapy NDA: 130 working days with enhanced regulatory engagement throughout the development process, including pre-NDA meetings and rolling review of submission modules.
• Conditional Approval: 130–200 working days. Products addressing life-threatening diseases with surrogate endpoint data may receive conditional market approval, with post-market confirmatory studies required.

Clinical Trial Duration — A Critical Component of the Total Timeline

While the regulatory review periods above cover the CDE’s evaluation time, the overall timeline from IND to market approval for CGT products is dominated by the clinical trial phase itself. Unlike traditional drugs, cell and gene therapy trials in China have unique characteristics that affect duration:

Phase I (Safety and Dosing)

For CGT products, Phase I trials typically enroll 10–30 patients and focus on dose escalation and safety profiling. These trials generally take 12–24 months, depending on the patient recruitment rate, which can be faster in China for certain oncology indications due to the large patient population and centralized referral networks.

Phase II (Dose Optimization and Proof of Concept)

Phase II trials for CGT products usually enroll 30–100 patients and require 18–36 months. The duration is heavily influenced by the follow-up period required to demonstrate durable responses, which for CAR-T therapies and gene therapies may need 6–12 months of observation.

Phase III (Pivotal/Confirmatory)

Pivotal trials for CGT market authorization typically enroll 100–500 patients and span 24–48 months. However, China’s regulatory pathway increasingly accepts single-arm pivotal trials for CGT products targeting rare diseases or cancers with high unmet need, which can reduce both enrollment requirements and trial duration.

Accelerated Pathways and Their Impact on Review Timelines

China has established several regulatory pathways that can significantly reduce the total time from IND to market for qualifying CGT products. These pathways are particularly relevant given the rapidly evolving nature of cell and gene therapy:

Specific Examples: How Long Did Approved CGT Products Take?

Examining real-world examples of cell and gene therapy products that have received NMPA approval provides practical benchmarks:

CAR-T Products — A Benchmark

The first CAR-T cell therapies approved in China — Yescarta (Axicabtagene Ciloleucel) by Fosun Kite and Relma-cel (Relmacabtagene Autoleucel) by JW Therapeutics — followed different timelines. Yescarta, relying on global clinical data, received NMPA approval in June 2021, approximately 2.5 years after IND filing in China. Relma-cel, developed with local clinical trials, received approval in September 2021, approximately 4 years after its IND filing. This comparison illustrates how leveraging overseas clinical data can dramatically compress the timeline.

Emerging Gene Therapies

As of 2025–2026, no fully domestic gene therapy product has received NMPA market approval for a genetic disease, though several are in late-stage development. Based on current CDE review patterns, the expected timeline for gene therapy products in China is:

• IND to NDA (full development in China): 5–7 years
• IND to NDA (bridging study using overseas data): 2–4 years
• IND to Conditional Approval (with surrogate endpoint): 2–3 years

Factors That Can Extend the NMPA Review Period

Several factors specific to cell and gene therapy products can prolong the review period beyond the standard timelines:

Manufacturing Complexity and GMP Compliance

CGT product manufacturing is inherently complex, and the CDE has increasingly stringent requirements for Chemistry, Manufacturing, and Controls (CMC) documentation. Autologous CAR-T therapies, for example, require rigorous chain-of-identity documentation from apheresis through infusion. Inadequate CMC data is the single most common reason for IND clinical holds and NDA review extensions in China, accounting for approximately 45% of review delays according to industry surveys.

Long-Term Follow-Up Requirements

The CDE’s 2021 Technical Guidance for Long-term Follow-up of Gene Therapy Products requires sponsors to monitor patients for 5 years (or longer, depending on vector characteristics). While this does not extend the initial regulatory review, it affects the completeness of the safety database required for NDA submission, which may require longer clinical trial durations.

Multi-Omics and Biomarker Data Requirements

The CDE increasingly expects sponsors to include comprehensive biomarker and translational research data in their submissions, which can add 6–12 months to the preclinical and early clinical development phases for CGT products.

Strategies to Optimize Review Timeline

Foreign biotech companies can adopt several strategies to minimize the NMPA review period for their CGT products:

• Apply for Breakthrough Therapy Designation Early. Submit BTD applications as early as Phase I — the CDE has shown a 78% approval rate for oncology CGT products applying for this designation. The enhanced CDE guidance throughout development reduces the risk of major review deficiencies at the NDA stage.
• Leverage Overseas Clinical Data. Submit clinical data from ICH-region trials whenever possible. The CDE accepts overseas data under the 2018 Technical Guidelines for Acceptance of Overseas Clinical Trial Data, potentially reducing the required China-specific clinical data by 50–70%.
• Utilize Pre-IND Communication Meetings. Request a Type A or Type B communication meeting with the CDE before formal IND submission. This allows the sponsor to align with CDE expectations on trial design, patient population, and CMC requirements, reducing the risk of clinical hold or major review questions.
• Engage a Qualified China Regulatory Partner. Work with a local CRO or regulatory affairs consultancy that has specific experience with CGT products and established relationships with CDE reviewers.
• Consider First-in-Human Trials in China. For products primarily targeting Chinese patient populations, conducting the first-in-human trial in China eliminates the need for bridging studies and can surprisingly accelerate the overall timeline by 12–18 months compared to sequential overseas-then-China development.

Conclusion

The NMPA review period for cell and gene therapy products in China ranges from approximately 60 working days for IND approval to 130–200 working days for NDA/BLA review. However, the total timeline from IND to market approval — including clinical development — typically spans 3–5 years for products leveraging accelerated pathways and overseas data, and 5–7 years for products requiring full development within China.

China’s regulatory environment for CGT products has become increasingly supportive, with the CDE showing genuine willingness to engage in early dialogue and apply flexible regulatory pathways. For foreign biotech companies with innovative CGT products, the Chinese market offers a regulatory pathway that is both rigorous and potentially faster than the US FDA or EMA timelines when the appropriate expedited pathways are utilized effectively. Strategic planning around regulatory designation applications, clinical data generation, and early CDE engagement are the key levers for minimizing review times and achieving timely market access.